News about Clinical Trials

Sun Pharma Presents Long-Term Leqselvi Data

Sun Pharma presents long-term safety and efficacy data for Leqselvi in adults with severe alopecia areata at the EADV Congress 2026.

Clinical Trials | 03/10/2026 | By News Bureau

Roche Reports New Real-World Vabysmo Data Across Retinal Conditions

Roche’s VOYAGER study provides real-world data on Vabysmo’s effectiveness, durability and safety across multiple retinal conditions.

Clinical Trials | 03/10/2026 | By News Bureau

Pierre Fabre Resubmits Tabelecleucel BLA to FDA

Pierre Fabre Pharmaceuticals resubmits tabelecleucel BLA for treatment of Epstein-Barr virus positive -post-transplant lymphoproliferative disease to the FDA.

Clinical Trials | 03/10/2026 | By News Bureau

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Clinical Trials | 01/10/2026 | By News Bureau

Acurx Enrolls First Patient in PATHFINDER C. difficile Trial

Acurx Pharmaceuticals has announced the first patient enrolled in PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.

Clinical Trials | 01/10/2026 | By News Bureau

Lilly's Zepbound Shows More Weight Loss Than Wegovy HD in Analysis

Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with greater weight loss than Wegovy HD (semaglutide 7.2 mg) in an indirect comparison.

Clinical Trials | 01/10/2026 | By News Bureau

Silexion Reports Positive Findings for RNAi Candidate SIL204

Silexion Therapeutics reports new findings supporting the cellular uptake and gene-silencing mechanism of its investigational RNAi candidate SIL204.

Clinical Trials | 30/09/2026 | By News Bureau

Mirum's Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta

Mirum Pharmaceuticals reports positive Phase 3 AZURE-1 results for brelovitug, with the investigational antibody meeting its primary endpoint in chronic HDV.

Clinical Trials | 29/09/2026 | By News Bureau

Innovent Expands Phase 3 MarsLight-11 NSCLC Study

Innovent expands the global phase 3 MarsLight-11 study of IBI363/TAK-928 in immunotherapy-resistant NSCLC to include non-squamous NSCLC patients.

Clinical Trials | 29/09/2026 | By News Bureau

BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma

Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.

Clinical Trials | 28/09/2026 | By News Bureau